Rossari Biotech Ltd (IN:ROSSARI)
:ROSSARI
Want to see IN:ROSSARI full AI Analyst Report?
ROSSARI Stock Chart & Stats
₹583.95
₹39.25(5.10%)
At close: 4:00 PM EST
₹583.95
₹39.25(5.10%)
Day’s Range― - ―
52-Week Range₹372.90 - ₹767.55
Previous CloseN/A
Volume112.05K
Average Volume (3M)2.66K
Market Cap
₹27.72B
Enterprise Value₹31.40B
Total Cash (Recent Filing)₹719.76M
Total Debt (Recent Filing)₹3.53B
Price to Earnings (P/E)11.4
Beta0.93
Next Earnings
Jul 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.09%
Share Statistics
EPS (TTM)24.68
Shares Outstanding55,383,366
10 Day Avg. Volume1,386
30 Day Avg. Volume2,661
Financial Highlights & Ratios
PEG Ratio1.51
Price to Book (P/B)1.57
Price to Sales (P/S)0.87
P/FCF Ratio-9.55
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)32.36
Revenue Forecast (FY)₹26.68B
Bulls Say, Bears Say
Bulls Say
Sustained Revenue GrowthConsistent multi-year revenue expansion indicates durable commercial traction across product lines and end markets. This steady top-line base supports scale economies, predictable B2B recurring sales, and provides a foundation for reinvestment and cross-selling over the next 2–6 months and beyond.
Diversified End-market ExposureServing multiple end markets reduces single-industry cyclicality and allows portfolio-level stability. Diversification supports steady demand across cycles, enables cross-selling of formulations, and helps absorb softness in any one vertical, strengthening medium-term revenue resilience.
Reasonably Healthy Balance Sheet BaseA growing equity base and only moderate leverage provide a buffer against volatility and fund strategic investments. Even with higher debt, the balance sheet strength grants financial flexibility to support working-capital needs and capex over the coming months without immediate solvency risk.
Bears Say
Weak Cash GenerationPersistently negative and volatile cash conversion undermines internal funding for capex and working capital. Over 2–6 months this reduces flexibility, raises refinancing risk, and forces reliance on external funding or higher borrowing costs, constraining strategic options.
Rising Debt And Higher LeverageA material increase in debt elevates interest obligations and financial risk, limiting the firm's ability to absorb shocks or pursue growth initiatives. Coupled with weak cash flow, rising leverage heightens refinancing and covenant risks over the medium term.
Margin Deterioration In 2026A meaningful gross-margin decline signals cost pressure or adverse pricing/mix that can structurally compress returns. If sustained, lower margins will reduce cash flow generation and return on capital, making deleveraging and reinvestment harder over the next several quarters.
Rossari Biotech Ltd News
ROSSARI FAQ
What was Rossari Biotech Ltd’s price range in the past 12 months?
Rossari Biotech Ltd lowest stock price was ₹372.90 and its highest was ₹767.55 in the past 12 months.
What is Rossari Biotech Ltd’s market cap?
Rossari Biotech Ltd’s market cap is ₹27.72B.
When is Rossari Biotech Ltd’s upcoming earnings report date?
Rossari Biotech Ltd’s upcoming earnings report date is Jul 27, 2026 which is in 67 days.
How were Rossari Biotech Ltd’s earnings last quarter?
Rossari Biotech Ltd released its earnings results on Apr 27, 2026. The company reported ₹8.3 earnings per share for the quarter, beating the consensus estimate of ₹6.3 by ₹2.
Is Rossari Biotech Ltd overvalued?
According to Wall Street analysts Rossari Biotech Ltd’s price is currently Overvalued.
Does Rossari Biotech Ltd pay dividends?
Rossari Biotech Ltd pays a Annually dividend of ₹0.5 which represents an annual dividend yield of 0.09%. See more information on Rossari Biotech Ltd dividends here
What is Rossari Biotech Ltd’s EPS estimate?
Rossari Biotech Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Rossari Biotech Ltd have?
Rossari Biotech Ltd has 55,383,366 shares outstanding.
What happened to Rossari Biotech Ltd’s price movement after its last earnings report?
Rossari Biotech Ltd reported an EPS of ₹8.3 in its last earnings report, beating expectations of ₹6.3. Following the earnings report the stock price went down -1.947%.
Which hedge fund is a major shareholder of Rossari Biotech Ltd?
Currently, no hedge funds are holding shares in IN:ROSSARI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Rossari Biotech Ltd
Rossari Biotech Limited engages in manufacture and sale of specialty chemicals in India and internationally. It offers soap and detergents; inks, paints, and coatings; ceramics and tiles; pulp and papers; cement; and water treatment solutions. The company also provides textile specialty chemicals, such as cotton, polyester, acrylic, wool, silk, nylon, functional finishes, denim, and sustainable solutions; and pet grooming products, which include natural pet shampoos, powders, deodorants, sprays, creams, and floor washing liquids under the Lozalo, Hunger Fills, and Sniffy brand names. In addition, it provides poultry nutrition products comprising vitamin-mineral formulations, toxin binders, individual and cocktail enzymes, liquid nutraceuticals, and supplements or herbal preparations. The company was formerly known as Rossari Labtech and changed its name to Rossari Biotech Limited in December 2003. Rossari Biotech Limited was founded in 2003 and is based in Mumbai, India.
Technical Analysis
Balaji Amines Limited
―
Fineotex Chemical Limited
―
Galaxy Surfactants Ltd.
―
Kiri Industries Limited
―
Tatva Chintan Pharma Chem Limited
―